|
|
SAF-1 |
|
Vaxjo ID |
96 |
|
Vaccine Adjuvant Name |
SAF-1 |
|
Alternative Names |
SAF-m; Syntex Adjuvant Formulation |
|
Adjuvant VO ID |
VO_0001349
|
|
Stage of Development |
Clinical Trial |
|
Structure |
Composed of threonyl-MDP (0.05-1%) in an emulsion vehicle [5% squalane, 2.5% Pluronic® L121, 0.2% Polysorbate 80 and phosphate buffered saline (pH 7.4)] (Vogel and Powell, 1995). |
|
Appearance |
White, fluid, oil-in-water emulsion. |
|
Storage |
≥30° C. |
|
Function |
Antigens become arranged on the surface of the emulsion droplets partly because of their amphipathic nature, and partly because of hydrogen bonding with poloxamer 401. The emulsion droplets also activate complement, as demonstrated by consumption of C3 and production of C3b; the latter, on the surface of droplets, targets them to antigen-presenting cells (follicular dendritic cells and interdigitating cells) in lymph nodes of the drainage chain and possibly in more distant lymphoid tissues. In this way the emulsion facilitates the presentation of antigens to responding lymphocytes (Vogel and Powell, 1995). |
|
Safety |
At therapeutic doses, no safety concern is anticipated. Dose is indication dependent, but a typical volume of injection is 1 mL (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
